Exit 156 Capital
Growth-focused investment firm that provides non-controlling growth capital and operational support to small and middle-market companies in healthcare services, medical devices/diagnostics, technology, and consumer wellness. The firm emphasizes partnerships with management teams, a concentrated portfolio approach, and using a network of operating partners to accelerate commercialization and growth.
Industries
Nr. of Employees
small (1-50)
Exit 156 Capital
Services
Direct equity investments to accelerate scaling and commercialization for growth-stage companies.
Hands-on support with management teams on strategy, commercialization, and operational improvements.
Support for clinical study expansion, regulatory strategy, and pathways toward product clearance and market entry.
Direct equity investments to accelerate scaling and commercialization for growth-stage companies.
Hands-on support with management teams on strategy, commercialization, and operational improvements.
Support for clinical study expansion, regulatory strategy, and pathways toward product clearance and market entry.
Expertise Areas
- Growth capital investing
- Healthcare services and digital health
- Medical device and diagnostic commercialization
- Digital marketplace and mobile app platforms for staffing
Key Technologies
- Point-of-care breath-based diagnostics
- Non-invasive biomarker detection (exhaled nitric oxide)
- Mobile app marketplace platforms for staffing
- Digital health platform development
News & Updates
Announcement of a $2.0M investment to support development and clinical expansion of a non-invasive, point-of-care breath-based sepsis screening diagnostic.
Announcement of a $2.0M investment to accelerate a tech-enabled nurse staffing mobile platform and complete its Series A round.
Announcement of a $1.0M investment to support product development and scaling of allergen-friendly, plant-based food products.
Opinion/analysis piece outlining trends and investment themes in health systems, digital health disruption, rural healthcare access, and consolidation impacts.
Announced initial portfolio investments in diagnostic, consumer wellness, and digital health companies less than one year after firm launch.
Announcement of a $2.0M investment to support development and clinical expansion of a non-invasive, point-of-care breath-based sepsis screening diagnostic.
Announcement of a $2.0M investment to accelerate a tech-enabled nurse staffing mobile platform and complete its Series A round.
Announcement of a $1.0M investment to support product development and scaling of allergen-friendly, plant-based food products.
Opinion/analysis piece outlining trends and investment themes in health systems, digital health disruption, rural healthcare access, and consolidation impacts.
Announced initial portfolio investments in diagnostic, consumer wellness, and digital health companies less than one year after firm launch.